Lärkberget (LARK) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
20 Aug, 2026Executive summary
Focus during H1 2026 was on consolidating and stabilizing after a strategic shift to a pure investment company model, emphasizing responsible management of holdings and cost control.
NAXS remains a core portfolio holding, providing significant dividend income and influencing NAV development.
A planned rights issue of approximately 14.9 MSEK was evaluated but ultimately canceled due to market conditions.
A new board was elected at the AGM, initiating a review of strategic alternatives to maximize shareholder value.
Financial highlights
Result after financial items for Jan–Jun 2026 was 1,221 TSEK, a marked improvement from -12,339 TSEK in the same period 2025, mainly due to lower costs and higher dividend and interest income.
Net sales for the period were 252 TSEK, with total income including dividends and interest at 3,248 TSEK.
Cash flow for the period was 518 TSEK, compared to -13,466 TSEK in H1 2025.
Cash and cash equivalents at period end were 3,112 TSEK (60,282 TSEK at H1 2025).
Outlook and guidance
Ongoing review of strategic alternatives to enhance shareholder value, with further updates expected in H2 2026.
The company’s financial position and existing investments are considered sufficient to finance ongoing operations.
Latest events from Lärkberget
- Shifted to investment focus, posted positive H2, and grew NAV per share to 3.08 SEK.LARK
Q4 2025 - Strategic shift to investment focus completed; strong cash, first investments imminent.LARK
Q2 2025 - Strategic Partner A/S proposes a new board led by Luca Di Stefano for CombiGene.LARK
Investor Update - Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026.LARK
Q3 2024 - CG01 rights regained, CGT2 discontinued, COZY advanced; sales and cash declined year-over-year.LARK
Q2 2024 - CombiGene halts R&D, posts SEK 44.9m loss, and shifts focus to investments or dividends.LARK
Q4 2024